Our recent studies have shown that stage II and III high-risk estrogen receptor positive (ER + ) breast cancer cells upregulate growth factor receptors to amplify alternatives to estrogen growth signaling after treatment with endocrine and cell cycle therapy to bypass cell cycle arrest and promote resistance10. This evidence concerns the gene ESR1 and breast cancer.